RAC 2.20% $1.78 race oncology ltd

ASH2023 - Sheba 2.0, page-64

  1. 2,934 Posts.
    lightbulb Created with Sketch. 1305
    If the trial results were "rather impressive" using a clofarabine, fludarabine combination. Why does this support further studies of Bisantrene-based combinations with venetoclax or hypomethylating agents?



 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.